KPTI (Karyopharm Therapeutics Inc.) Earnings per share for the last four quarters

Public company logo of Karyopharm Therapeutics, Inc. (KPTI)

Karyopharm Therapeutics (KPTI) maintains a stable position thanks to Xpovio, although patent expirations and new competition are eroding its market advantages. High sales margins are offset by promotion costs and the development of new products, which impacts free cash flow, currently standing at 11.80. This EPS (TTM) chart, which clearly demonstrates pricing changes, reveals the profit dynamics. Meanwhile, the automation of substance synthesis is supplemented by mandatory medical supervision of clinical trials.

KPTI Karyopharm Therapeutics Inc. Earnings per share for the last twelve months (02/11/2024 - 11/18/2026)

Karyopharm - analytical breakdowns and key metrics (KPTI)

- business market valuation indicators:
Signature product of Karyopharm Therapeutics, Inc.

This indicator reflects the percentage change in trailing twelve-month (TTM) earnings per share over a year, capturing the sensitivity of the bottom line to operating expenses and revenue. For Karyopharm Therapeutics (KPTI), whose success depends on its R&D pipeline and capital burn rate control, measuring the annual EPS TTM growth allows for an assessment of resource management efficiency before the company achieves stable commercial profitability.

Competitor analysis for Karyopharm Therapeutics

Earnings per share for the trailing year GMAB (Genmab US)|EXEL (Exelixis) - Net earnings per share for the last 12 months|NUVL: Earnings per share for the last four quarters|KYMR (Kymera Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) ideayabio.com|Earnings per share for the last twelve months Enliven Therapeutics, Inc. (ELVN)|ORIC (ORIC Pharmaceuticals, Inc.) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) RLAY (Relay Therapeutics Inc)|Net earnings per share for the trailing year Nurix Pharma|Tyra Biosciences Inc - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Verastem|GLUE (Monte Rosa Therapeutics) - Net earnings per share for the last 12 months|CGEM: Earnings per share for the last four quarters|IMRX (immuneering.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months C4 Tx CCCC|Net earnings per share (EPS TTM) BDTX|Repare Therapeutics Inc. - Earnings per share for the last 12 months|PMV Pharmaceuticals, Inc. - Net earnings per share for the last 12 months|Earnings per share for the trailing year PPCB|BGMS: Net earnings per share for the last 12 months|aadibio.com - Earnings per share for the last four quarters|ALRN: Net earnings per share (EPS TTM)|Blueprint Medicines Corp. - Earnings per share for the trailing year|GLYC (GlycoMimetics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months SpringWorks Therapeutics Inc. SWTX